Akèy › Limfòm selil B › New York › New York City
Etid klinik pou Limfòm selil B nan New York City, NY
18 etid pou Limfòm selil B ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Ap rekriteFaz 3
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Ap rekriteFaz 2
- Research Site, New York
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Ap rekriteFaz 1/2
- Icahn School of Medicine At Mount Sinai, New York
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- ak 1 plis
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Ap rekriteFaz 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Ap rekriteFaz 1/2
- Research Site, New York
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Ap rekriteFaz 1
- Clinical Trial Site, New York
- Clinical Trial Site, New York
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1/2
- Research Site, New York
A Study of ARC-02 in B-cell NHL
Ap rekriteFaz 1
- NYU Langone, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Ap rekriteFaz 1/2
- Research Site, New York
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Ap rekriteFaz 1/2
- Memorial Sloan Kettering, New York
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Ap rekriteFaz 2
- Columbia University Irving Medical Center, New York
Study of CAR-T Therapy in Older Patients
Ap rekriteEtid obsèvasyon
- Memorial Sloan Kettering Cancer Center, New York
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Ap rekrite
- Columbia University, New York
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Ap rekrite
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
- NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only), New York
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Ap rekriteFaz 1
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
Etid Limfòm selil B nan lòt vil
- Houston, TX16 etid
- Chicago, IL13 etid
- Nashville, TN11 etid
- Philadelphia, PA11 etid
- Rochester, MN10 etid
- Milwaukee, WI9 etid
- Baldwin Park, CA9 etid
- Cleveland, OH9 etid
- Boston, MA8 etid
- Salt Lake City, UT8 etid
- Washington, DC7 etid
- Charlotte, NC7 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.